Novozymes A/S - Company Profile (NASDAQ:NVZMY)

About Novozymes A/S - (NASDAQ:NVZMY)

Novozymes A/S - logoNovozymes A/S is a Denmark-based biotechnology company engaged in the production and sale of industrial enzymes, microorganisms and biopharmaceutical ingredients. The Company operates in four geographical regions: Europe, Middle East & Africa (including Denmark), North America, Asia Pacific and Latin America. It develops and distributes solutions within the market areas agriculture, bioenergy, food & beverages, household care, leather, pharmaceuticals, forest products, textile and wastewater solutions. Novozymes operates through a range of partnerships with companies, such as Adisseo, Beta Renewables, DONG Energy and Monsanto, and is a parent company of Novozymes Belgium BVBA, Novozymes BioAg Limited, Novozymes Canada Limited, Albumedix A/S and Organobalance GmbH, among others.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: NASDAQ:NVZMY
  • CUSIP: N/A
  • Web:
Average Prices:
  • 50 Day Moving Avg: $51.66
  • 200 Day Moving Avg: $46.37
  • 52 Week Range: $31.57 - $52.99
  • Trailing P/E Ratio: 31.48
  • Foreward P/E Ratio: 27.91
  • P/E Growth: 24.78
Sales & Book Value:
  • Annual Revenue: $2.32 billion
  • Price / Sales: N/A
  • Book Value: $5.83 per share
  • Price / Book: 8.90
  • Dividend Yield: 1.1%
  • EBITDA: $811.86 million
  • Average Volume: 20,158 shs.

Frequently Asked Questions for Novozymes A/S - (NASDAQ:NVZMY)

What is Novozymes A/S -'s stock symbol?

Novozymes A/S - trades on the NASDAQ under the ticker symbol "NVZMY."

How were Novozymes A/S -'s earnings last quarter?

Novozymes A/S - (NASDAQ:NVZMY) posted its quarterly earnings data on Friday, August, 11th. The company reported $0.36 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $0.39 by $0.03. The firm had revenue of $522.72 million for the quarter. View Novozymes A/S -'s Earnings History.

Where is Novozymes A/S -'s stock going? Where will Novozymes A/S -'s stock price be in 2017?

5 brokerages have issued 1 year price objectives for Novozymes A/S -'s shares. Their predictions range from $48.00 to $48.00. On average, they expect Novozymes A/S -'s stock price to reach $48.00 in the next year. View Analyst Ratings for Novozymes A/S -.

Who are some of Novozymes A/S -'s key competitors?

Who are Novozymes A/S -'s key executives?

Novozymes A/S -'s management team includes the folowing people:

  • Joergen Buhl Rasmussen, Chairman of the Board
  • Peder Holk Nielsen, President, Chief Executive Officer
  • Agnete Raaschou-Nielsen, Vice Chairman of the Board
  • Thomas Videbaek, Chief Operating Officer; Executive Vice President, Research, Innovation & Supply
  • Andrew Fordyce, Executive Vice President, Food & Beverages
  • Anders Lund, Executive Vice President, Household Care & Technical
  • Tina Sejersgaard Fanoe, Executive Vice President, Agriculture & Bioenergy
  • Lena Bech Halskov, Director, Employee Representative
  • Lars Hall Green, Director
  • Anders Hentze Knudsen, Director, Employee Representative

How do I buy Novozymes A/S - stock?

Shares of Novozymes A/S - can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Novozymes A/S -'s stock price today?

One share of Novozymes A/S - stock can currently be purchased for approximately $51.91.

MarketBeat Community Rating for Novozymes A/S - (NASDAQ NVZMY)
Community Ranking:  1.6 out of 5 (star)
Outperform Votes:  36 (Vote Outperform)
Underperform Votes:  76 (Vote Underperform)
Total Votes:  112
MarketBeat's community ratings are surveys of what our community members think about Novozymes A/S - and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Novozymes A/S - (NASDAQ:NVZMY) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 3 Hold Ratings, 1 Buy Rating
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $48.00 (7.53% downside)
Consensus Price Target History for Novozymes A/S - (NASDAQ:NVZMY)
Price Target History for Novozymes A/S - (NASDAQ:NVZMY)
Analysts' Ratings History for Novozymes A/S - (NASDAQ:NVZMY)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/14/2017Jefferies Group LLCSet Price TargetHold$48.00LowView Rating Details
2/10/2017J P Morgan Chase & CoDowngradeOverweight -> NeutralN/AView Rating Details
2/1/2017Goldman Sachs Group IncDowngradeNeutral -> SellN/AView Rating Details
1/5/2017Sanford C. BernsteinUpgradeMarket Perform -> OutperformN/AView Rating Details
11/1/2016Berenberg BankUpgradeSell -> HoldN/AView Rating Details
10/7/2016Deutsche Bank AGInitiated CoverageHoldN/AView Rating Details
(Data available from 10/21/2015 forward)


Earnings History for Novozymes A/S - (NASDAQ:NVZMY)
Earnings by Quarter for Novozymes A/S - (NASDAQ:NVZMY)
Earnings History by Quarter for Novozymes A/S - (NASDAQ NVZMY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/11/20176/30/2017$0.39$0.36$522.72 millionViewN/AView Earnings Details
4/26/20173/31/2017$0.36$0.37$535.97 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Novozymes A/S - (NASDAQ:NVZMY)
Current Year EPS Consensus Estimate: $1.69 EPS
Next Year EPS Consensus Estimate: $1.86 EPS


Dividend History for Novozymes A/S - (NASDAQ:NVZMY)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Novozymes A/S - (NASDAQ:NVZMY)
No insider trades for this company have been tracked by


Headline Trends for Novozymes A/S - (NASDAQ:NVZMY)
Latest Headlines for Novozymes A/S - (NASDAQ:NVZMY)
Loading headlines, please wait.



Novozymes A/S - (NVZMY) Chart for Saturday, October, 21, 2017

This page was last updated on 10/21/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.